Indication
central nervous system primary tumor
2 clinical trials
2 products
Clinical trial
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem GliomaStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Product
APX005MClinical trial
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
INCB7839